{"id":888565,"date":"2025-09-22T21:40:08","date_gmt":"2025-09-23T01:40:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/"},"modified":"2025-09-22T21:40:08","modified_gmt":"2025-09-23T01:40:08","slug":"alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/","title":{"rendered":"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW YORK<\/span>
\n <\/span>, Sept. 22, 2025<\/span><\/span> \/PRNewswire\/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023<\/span> and June 25, 2025<\/span>, both dates inclusive (the “Class Period”), of the important\u00a0October 6, 2025 lead plaintiff deadline.<\/p>\n

\n

\n
\n \"LOGO
\n <\/a>\n <\/p>\n<\/p><\/div>\n

So What: If you purchased Altimmune\u00a0securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

What to do next:\u00a0To join the Altimmune class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=22535<\/a> or call Phillip Kim, Esq.<\/span> at 866-767-3653 or email case@rosenlegal.com<\/a> for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than October 6, 2025<\/span>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.\u00a0Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million<\/span> for investors. In 2020, founding partner Laurence Rosen<\/span> was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

Details of the case: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to the results of Altimmune’s IMPACT Phase 2b<\/span> MASH trial. In truth, Altimmune failed to meet an important statistical significance marker relating to the fibrosis reduction primary endpoint. Altimmune had consistently touted its inflated expectations for positive topline results from the IMPACT Phase 2b<\/span> MASH trial, while concealing higher responses in the placebo group, which they knew or should have known would negatively impact the topline results. Altimmune’s IMPACT Phase 2b<\/span> MASH trial results fell short of reality, as shown by Altimmune’s topline data, which show that the statistical significance was not achieved for the fibrosis reduction primary endpoint. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the Altimmune class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=22535<\/a> or call Phillip Kim, Esq.<\/span> at 866-767-3653 or email case@rosenlegal.com<\/a> for more information.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

Contact Information:<\/p>\n

\n Laurence Rosen, Esq.<\/span>
\n
\n Phillip Kim, Esq.<\/span>
\n
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY<\/span> 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com<\/a>
www.rosenlegal.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-302563595.html<\/a><\/p>\n

SOURCE THE ROSEN LAW FIRM, P. A.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , Sept. 22, 2025 \/PRNewswire\/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the “Class Period”), of the important\u00a0October 6, 2025 lead plaintiff deadline. So What: If you purchased Altimmune\u00a0securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the Altimmune class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=22535 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must … <\/p>\n

Continue reading “ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-888565","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Sept. 22, 2025 \/PRNewswire\/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the “Class Period”), of the important\u00a0October 6, 2025 lead plaintiff deadline. So What: If you purchased Altimmune\u00a0securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the Altimmune class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=22535 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must … Continue reading "ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T01:40:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit\",\"datePublished\":\"2025-09-23T01:40:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/\"},\"wordCount\":657,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/\",\"name\":\"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"datePublished\":\"2025-09-23T01:40:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/","og_locale":"en_US","og_type":"article","og_title":"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire NEW YORK , Sept. 22, 2025 \/PRNewswire\/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the “Class Period”), of the important\u00a0October 6, 2025 lead plaintiff deadline. So What: If you purchased Altimmune\u00a0securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the Altimmune class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=22535 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must … Continue reading \"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-23T01:40:08+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit","datePublished":"2025-09-23T01:40:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/"},"wordCount":657,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/","name":"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","datePublished":"2025-09-23T01:40:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=888565"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888565\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=888565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=888565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=888565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}